Study of Factors Predicting Response to Steroid Treatment in Adults Newly Diagnosed with Polymyalgia Rheumatica or Giant Cell Arteritis

What this Trial Is About

Researchers are exploring factors that predict how patients with newly diagnosed polymyalgia rheumatica PMR and giant cell arteritis GCA respond to steroid treatment. These related inflammatory diseases are typically treated with glucocorticoids GCs, but individual responses vary widely. This study aims to understand the relationship between natural steroid hormone levels and treatment outcomes to help tailor therapies and reduce side effects like osteoporosis and infections. Participants with PMR will receive oral prednisone starting at 15 mg per day, tapered gradually as symptoms improve. Those with GCA will follow a guideline-based prednisone regimen starting at 1 mg per kg of body weight and tapering to zero by 26 weeks. Biological samples will be collected at three points after initial prednisone treatment, during tapering, and after stopping steroids, to analyze cellular responses, hormone levels, and steroid metabolism. Throughout the study, clinical data will be recorded in a database, tracking relapses, cumulative steroid doses, use of additional immunosuppressive treatments, and steroid-related toxicity. The primary outcome is whether patients experience relapse within one year of diagnosis. Various laboratory measurements and correlations will help identify steroid response profiles, with the total study duration extending up to one year after diagnosis.

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis